Trials soon ready
Clinical trials expected to report results within the next 6 months, ranked by how much the coming result could matter. Each trial shows its estimated finish date, explained in plain language.
This page shows companies working on cures and vaccines first, on purpose. We believe investor interest in cures leads to more cure trials. Why we do this.
Results due in the coming weeks
These trials are in their final phase, the companies running them are on the stock market, and results are due within weeks. A final-phase result is usually the last big test before a treatment can be approved, and it can move the company's value in either direction. We list them up top so you see the nearest dates first.
-
Gene therapy slows vision loss in stargardt disease trial Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
Sharper eye for prostate cancer: new imaging agent aims to spot hidden spread Results expected Sep 2026 (estimated) 🚀 Make-or-breakClarity Pharmaceuticals Ltd ASX: CU6
-
New hepatitis c pill aims to cut treatment time in half Results expected Sep 2026 (estimated) 🚀 Make-or-break
-
New hope for chronic hives: barzolvolimab in Late-Stage trial Results expected Oct 2026 (estimated) 🚀 Make-or-break
-
Rabies vaccine batch check: will it pass the test? Results expected Sep 2026 (estimated) 🚀 Make-or-breakSinovac Biotech Co., Ltd. NASDAQ: SVA
The weekly investor briefing
One email every Sunday: which trial results are due in the coming weeks, what read out in the past week, and the small companies with a make-or-break result ahead. Free, and every issue has a one-click unsubscribe.
We'll send one confirmation email first — you're not subscribed until you click it.
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
Cure OngoingThe purpose of this study is to evaluate the safety and preliminary activity of ARC-T cells and SPRX002 in participants with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS)
Results expected Oct 2026 (estimated)
Phase 1 • Sponsor: Arcellx, Inc. • Aim: Cure
Last updated Aug 13, 2026 00:00 UTC
Gilead Sciences, Inc. · GILD NASDAQ Trade on eToro (ad)Result impactModerateLarge company Follow-on study Readout in ~1 wkA follow-on study — an extension, safety or dosing run, not the deciding result.
-
Could one drug replace the standard triple therapy for rectal cancer?
Disease control OngoingThe purpose of this study is to investigate dostarlimab monotherapy in participants with locally advanced Mismatch-repair deficient (dMMR)/Microsatellite instability-high (MSI-H) rectal cancer who have received no prior treatment. Participants who achieve complete clinical respon…
Results expected Nov 2026 (estimated)
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
GSK · GSK NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 2 Readout in ~6 wkA large company. One readout moves the needle only so far.
-
New hope for advanced breast cancer: targeted drug combo tested in major trial
Disease control OngoingThe study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2 (HER2)-positive breast cancer as a first line of treatment…
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
May already have reported ↗ AstraZeneca · AZN NASDAQ Trade on eToro (ad)Result impactModerateMega-cap May already have reported Readout in ~2 moThe company has filed about this drug. The registry date may be out of date.
Sponsor filing, 2026-03-16 → -
Engineered immune cells take aim at Hard-to-Treat leukemia
Cure Recruiting nowThe purpose of the study is to evaluate the safety and tolerability of B019 in subjects.
Results expected Dec 2026 (estimated)
Phase 1 • Sponsor: Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. • Aim: Cure
Last updated Aug 19, 2026 00:00 UTC
Shanghai Pharmaceuticals Holding Co., Ltd. · 601607 SSEResult impactLowLarge company Readout in ~3 moA large company. One readout moves the needle only so far.
-
Major RSV vaccine trial for seniors nears completion
Vaccine OngoingEfficacy Study: This randomized, double-blinded, placebo-controlled Phase 3 study is designed to assess the safety, immunogenicity, and efficacy of a single dose of RSVpreF in the prevention of LRTI-RSV in adults: * At a dose of 120µg. * In adults 60 years of age and older. * Th…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 09:00 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
New mRNA vaccine aims to stop the stomach flu
Vaccine OngoingThe primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prevent protocol-defined moderate or severe norovirus acute gastroenteritis (AGE) associated with vaccine matched genotypes.
Results expected Feb 2027 (estimated)
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Jun 27, 2026 12:33 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~5 moA large company. One readout moves the needle only so far.
-
One-Time gene therapy could free hemophilia patients from frequent infusions
Disease control OngoingIn this study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by use of a viral vector to treat the disease. By replacing the defective gene with a heal…
Results expected Sep 2026 (estimated)
Phase 1/2 • Sponsor: Bayer • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
Bayer AG · BAYN XETRAResult impactModerateMega-cap Phase 2 Readout dueA large company. One readout moves the needle only so far.
-
New hope for EGFR lung cancer: Dato-DXd combo tested in phase 3 trial
Disease control Recruiting nowThis study will assess the effect of Dato-DXd in combination with osimertinib or Dato-DXd monotherapy versus platinum-based doublet chemotherapy in terms of progression-free survival (PFS).
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~1 wkA large company. One readout moves the needle only so far.
-
New drug cocktail aims to stall lung cancer progression
Disease control OngoingThis is a Phase III, randomised, double-blind, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) in combination with oleclumab (MEDI9447) or durvalumab (MEDI4736) with monalizumab (IPH2201) in adults with locally advanced (Stage III), unr…
Results expected Sep 2026 (estimated)
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~1 wkA large company. One readout moves the needle only so far.
-
One-Shot gene therapy could end monthly eye injections for wet AMD
Disease control OngoingABBV-RGX-314 (also known as RGX-314 and surabgene lomparvovec (sura-vec)) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD). Wet AMD is characterized by loss of vision due to new, leaky blood vess…
Results expected Oct 2026 (estimated)
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
AbbVie · ABBV NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~1 wkA large company. One readout moves the needle only so far.
-
New RSV vaccine candidate aims to shield older adults from severe lung infections
Vaccine OngoingThis Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.
Results expected Oct 2026 (estimated)
Phase 1/2 • Sponsor: AstraZeneca • Aim: Vaccine
Last updated Sep 03, 2026 00:00 UTC
AstraZeneca · AZN NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 2 Readout in ~2 wkA large company. One readout moves the needle only so far.
-
New pill aims to cut stroke risk without the bleeding worry
Disease control OngoingThe purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
Results expected Oct 2026 (estimated)
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
Johnson & Johnson · JNJ NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~3 wkA large company. One readout moves the needle only so far.
-
Kidney cancer combo aims to stop recurrence after surgery
Disease control OngoingThe purpose of this study is to assess the efficacy and safety of oral belzutifan (MK-6482) plus intravenous (IV) pembrolizumab (MK-3475) compared to placebo plus pembrolizumab, in the adjuvant treatment of Clear Cell Renal Cell Carcinoma (ccRCC) post nephrectomy. The primary st…
Results expected Oct 2026 (estimated)
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
Merck & Co., Inc. · MRK NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~5 wkA large company. One readout moves the needle only so far.
-
New obesity drug retatrutide takes on tirzepatide in major trial
Disease control OngoingThe main purpose of this study is to evaluate the efficacy and safety of retatrutide compared to tirzepatide in adults who have obesity. The study will last about 89 weeks.
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
Eli Lilly and Company · LLY NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~6 wkA large company. One readout moves the needle only so far.
-
New hope for Hard-to-Treat breast cancer: Head-to-Head drug trial launches
Disease control Recruiting nowThis is a Phase III, multicenter, randomized, open-label, global study designed to evaluate the efficacy and safety of inavolisib plus fulvestrant compared with alpelisib plus fulvestrant in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (H…
Results expected Nov 2026 (estimated)
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
Roche Holding AG · RHHBY OTCResult impactModerateMega-cap Phase 3, decisive Readout in ~2 moA large company. One readout moves the needle only so far.
-
New drug combo shows promise in High-Risk prostate cancer trial
Disease control OngoingThe purpose of this study is to determine if treatment with apalutamide plus androgen deprivation therapy (ADT) before and after radical prostatectomy (RP) with pelvic lymph node dissection (pLND) in participants with high-risk localized or locally advanced prostate cancer result…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
Johnson & Johnson · JNJ NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~2 moA large company. One readout moves the needle only so far.
-
Gene therapy could end frequent eye injections for wet AMD
Disease control OngoingABBV-RGX-314 (also known as RGX-314) is being developed as a novel one-time gene therapy for the treatment of neovascular (wet) age-related macular degeneration (wet AMD or nAMD). Wet AMD is characterized by loss of vision due to new, leaky blood vessel formation in the retina. W…
Results expected Dec 2026 (estimated)
Phase 2/3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
AbbVie · ABBV NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~2 moA large company. One readout moves the needle only so far.
-
Pfizer gives lyme vaccine a fifth dose — will it boost protection?
Vaccine Recruiting nowThe purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: * are generally healthy and 7 years of age and…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Pfizer • Aim: Vaccine
Last updated Jun 27, 2026 12:29 UTC
Pfizer · PFE NYSE Trade on eToro (ad)Result impactHighLarge company Phase 3, decisive Readout in ~2 moA large company. One readout moves the needle only so far.
-
Bladder cancer patients may skip surgery with new drug combo
Disease control OngoingThe purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
Johnson & Johnson · JNJ NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~3 moA large company. One readout moves the needle only so far.
-
New targeted combo aims to stall HER2+ breast cancer
Disease control Recruiting nowThis study will evaluate the efficacy and safety of inavolisib in combination with Phesgo (pertuzumab, trastuzumab, and rHuPH20 injection for subcutaneous use) compared with placebo in combination with Phesgo, as maintenance therapy, after induction therapy in participants with p…
Results expected Dec 2026 (estimated)
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
Roche Holding AG · RHHBY OTCResult impactModerateMega-cap Phase 3, decisive Readout in ~3 moA large company. One readout moves the needle only so far.
-
New vaccine aims to shield sickle cell kids from deadly infections
Vaccine Recruiting nowThe purpose of this study is to measure whether PCV21 vaccine (investigational pneumococcal vaccine) is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) compared with 20vPCV (licensed pneumococcal vaccine) when given as a single dose…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Sanofi • Aim: Vaccine
Last updated Jun 27, 2026 12:08 UTC
Sanofi · SNY NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
New combo therapy aims to outperform standard immunotherapy for lung cancer
Disease control OngoingThe purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) a…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
Merck & Co., Inc. · MRK NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
Can a new clotting factor offer better bleed protection for severe hemophilia?
Disease control OngoingPrimary Objective: \- To evaluate the long-term safety of BIVV001 in previously treated subjects with hemophilia A Secondary Objectives: * To evaluate the efficacy of BIVV001 as a prophylaxis treatment. * To evaluate the efficacy of BIVV001 in the treatment of bleeding episode…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
Sanofi S.A. · SNY NASDAQ Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
New mRNA shot targets bird flu: 4,000 volunteers needed
Vaccine OngoingThe purpose of this study is to evaluate humoral immunogenicity after 2 doses of mRNA-1018-H5, and to evaluate the safety and reactogenicity of mRNA-1018-H5 in adults ≥18 years of age.
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: ModernaTX, Inc. • Aim: Vaccine
Last updated Aug 13, 2026 00:00 UTC
Moderna, Inc. · MRNA NASDAQ Trade on eToro (ad)Result impactModerateLarge company Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
New hope for Hard-to-Treat breast cancer: targeted pill combo in final testing
Disease control OngoingThe purpose of this study is to complement Study CBYL719C2301 (SOLAR-1) and obtain more comprehensive data on the efficacy and safety of alpelisib (BYL719) in combination with fulvestrant compared with placebo plus fulvestrant in men or postmenopausal women with HR-positive, HER2…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
Novartis AG · NVS NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
New drug combo aims to outdo chemo for advanced bladder cancer
Disease control OngoingThis study will enroll participants with urothelial cancer (UC). UC can include cancer of the bladder, kidney, or the tubes that carry pee through the body (ureter, urethra). This study will try to find out if the drugs disitamab vedotin with pembrolizumab works better than plati…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
Pfizer Inc. · PFE NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
New monthly shot aims to stop second heart attacks
Disease control OngoingThe research study is being done to see if ziltivekimab can be used to treat people who were admitted to hospital because of a heart attack. Ziltivekimab might reduce development of heart disease, thereby preventing new heart attacks or strokes. Participants will either get zilti…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
Novo Nordisk A/S · NVO NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
Immunotherapy plus chemoradiation may help bladder cancer patients keep their bladder
Disease control OngoingResearchers are looking for new ways to treat muscle-invasive bladder cancer (MIBC). MIBC is a type of cancer that has not spread from the muscles in the bladder to other parts of the body. MIBC is treated by having surgery to remove the bladder (cystectomy). Not all people choo…
Results expected Jan 2027 (estimated)
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
Merck & Co., Inc. · MRK NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~4 moA large company. One readout moves the needle only so far.
-
Gene therapy injection aims to halt fatal brain disease in babies
Disease control OngoingJ3Z-MC-OJAB is an open-label, Phase 1/2, multicenter study to evaluate the safety and efficacy of single-dose LY3884961 (formerly PR001) in infants diagnosed with Type 2 Gaucher disease (GD2). For each patient, the study will be approximately 5 years in duration. During the first…
Results expected Feb 2027 (estimated)
Phase 1/2 • Sponsor: Prevail Therapeutics • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
Eli Lilly and Company · LLY NYSE Trade on eToro (ad)Result impactLowMega-cap Phase 2 Readout in ~4 moA large company. One readout moves the needle only so far.
-
Could this IV drug tame lupus kidney flares?
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of IV antifrolumab in adult patients with Active Proliferative Lupus Nephritis
Results expected Feb 2027 (estimated)
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
May already have reported ↗ AstraZeneca · AZN NASDAQ Trade on eToro (ad)Result impactModerateMega-cap May already have reported Readout in ~5 moThe company has filed about this drug. The registry date may be out of date.
Sponsor filing, 2026-02-03 → -
New CAR-T therapy aims to wipe out myeloma cells
Disease control OngoingThe purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.
Results expected Feb 2027 (estimated)
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
Johnson & Johnson · JNJ NYSE Trade on eToro (ad)Result impactLowMega-cap Phase 2 Readout in ~5 moA large company. One readout moves the needle only so far.
-
New hope for Crohn's: phase 3 trial of risankizumab underway
Disease control OngoingCrohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the bowels. It can cause many different symptoms including abdominal pain, diarrhea, tiredness, and weight loss. This study will assess…
Results expected Mar 2027 (estimated)
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 26, 2026 14:25 UTC
AbbVie · ABBV NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~5 moA large company. One readout moves the needle only so far.
-
New combo shot aims for major weight loss in obesity trial
Disease control OngoingThis study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term. The study has 2 parts: The first part is called 'the main study' and the second part is called 'the extension study'. In the main study participants …
Results expected Mar 2027 (estimated)
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
Novo Nordisk A/S · NVO NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 3, decisive Readout in ~5 moA large company. One readout moves the needle only so far.
-
Two-Drug malaria punch targets faster cure in kids
Cure Recruiting nowThis was Cohort C2 of the Platform study (NCT05750628) to evaluate the efficacy and safety of Cipargamin + KLU156 in participants with uncomplicated Plasmodium falciparum malaria.
Results expected Feb 2027 (estimated)
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Cure
Last updated Sep 12, 2026 00:00 UTC
Novartis AG · NVS NYSE Trade on eToro (ad)Result impactModerateMega-cap Phase 2 Readout in ~5 moA large company. One readout moves the needle only so far.
Why cures and vaccines come first here
We built this site so people can find trials that might cure them. These investor pages work toward the same goal from the money side: they show companies working on cures and vaccines first, and we promote those companies on purpose. We believe investor interest in cures and vaccines means more money for the companies chasing them, and more cure and vaccine trials as a result.
Nothing is hidden by this. Every trial soon ready, whatever its aim, is on the full list . Rankings are computed from the public trial record and the company's size. No company can pay to be listed or ranked higher.
Not investment advice. This page lists publicly registered clinical trials and the companies running them, for information only. A trial finishing is not a result, and a result is not an approval. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. We think this page is more useful when you can go straight to somewhere that sells the stock, so the "Listed companies" view shows only companies our broker partner carries; switch to all sponsors for the unfiltered list. Ranking is never for sale: no company can pay to appear here or to place higher.